| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Federico Gatto, Anna Arecco, Jessica Amarù, Marica Arvigo, Claudia Campana, Angelo Milioto, Daniela Esposito, Gudmundur Johannsson, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Alessandra Pudd. Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. International journal of molecular sciences. vol 26. issue 2. 2025-01-25. PMID:39859181. |
acromegaly is a rare endocrine disorder caused by excessive growth hormone (gh) production, due, in the vast majority of cases, to the presence of a gh-secreting pituitary tumour. |
2025-01-25 |
2025-01-28 |
Not clear |
| Federico Gatto, Anna Arecco, Jessica Amarù, Marica Arvigo, Claudia Campana, Angelo Milioto, Daniela Esposito, Gudmundur Johannsson, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Alessandra Pudd. Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. International journal of molecular sciences. vol 26. issue 2. 2025-01-25. PMID:39859181. |
acromegaly treatment aims to normalize plasma gh and igf-1 levels using surgery, medical treatment, or radiotherapy. |
2025-01-25 |
2025-01-28 |
Not clear |
| Federico Gatto, Anna Arecco, Jessica Amarù, Marica Arvigo, Claudia Campana, Angelo Milioto, Daniela Esposito, Gudmundur Johannsson, Francesco Cocchiara, Davide Carlo Maggi, Diego Ferone, Alessandra Pudd. Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. International journal of molecular sciences. vol 26. issue 2. 2025-01-25. PMID:39859181. |
this literature review explores the impact of the currently available pharmacological therapies for acromegaly (first- and second-generation somatostatin receptor ligands, a gh receptor antagonist, and dopamine agonists) on glucose homeostasis. |
2025-01-25 |
2025-01-28 |
Not clear |
| G Occhi, G Voltan, S Chiloiro, A Bianchi, P Maffei, F Dassie, G Mantovani, G Del Sindaco, D Ferone, F Gatto, M Losa, S Cannavò, C Scaroni, F Ceccat. The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism. Journal of endocrinological investigation. 2025-01-22. PMID:39841390. |
a paradoxical increase in gh after oral glucose load (gh-par) characterizes about one-third of acromegaly patients and is associated with a better response to first-generation somatostatin receptor ligands (fg-srls). |
2025-01-22 |
2025-01-24 |
Not clear |
| Yuki Taki, Takashi Kono, Tatsuma Matsuda, Ryunosuke Kozu, Masanori Fujimoto, Ikki Sakuma, Naoko Hashimoto, Kentaro Horiguchi, Yoshinori Higuchi, Tomoaki Tanak. Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature. Endocrine journal. 2025-01-22. PMID:39842795. |
pasireotide (pas), a multireceptor somatostatin analog, has been demonstrated to effectively control hormone levels, including those of growth hormone (gh) and insulin-like growth factor 1 (igf-1), in patients with acromegaly. |
2025-01-22 |
2025-01-25 |
Not clear |
| Parminder Singh, Anil Gautam, Marissa Trujillo, James Galligan, Lisa Hensley, Pankaj Kapahi, Andrzej Bartk. Growth Hormone Excess Drives Liver Aging via increased Glycation stress. bioRxiv : the preprint server for biology. 2025-01-20. PMID:39829894. |
pathological conditions such as acromegaly or pituitary tumors result in elevated circulating gh levels, which have been implicated in a spectrum of metabolic disorders, potentially by regulating liver metabolism. |
2025-01-20 |
2025-01-23 |
mouse |
| David S McLaren, Nikolaos Kyriakakis, Khyatisha Seejore, Julie Lynch, Robert D Murra. Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality? Clinical endocrinology. 2024-12-31. PMID:39737607. |
with the current therapeutic modalities available to endocrinologists, control of gh and igf-i is now possible in almost all patients with acromegaly with multi-modality therapy. |
2024-12-31 |
2025-01-02 |
Not clear |
| David S McLaren, Nikolaos Kyriakakis, Khyatisha Seejore, Julie Lynch, Robert D Murra. Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality? Clinical endocrinology. 2024-12-31. PMID:39737607. |
despite biochemical control of gh and igf-i, patients with acromegaly continue to experience impaired quality of life. |
2024-12-31 |
2025-01-02 |
Not clear |
| Betina Biagetti, Marta Araujo-Castro, Mónica Marazuela, Manel Puig-Doming. Treatment of acromegaly-induced diabetes: an updated proposal. Pituitary. vol 28. issue 1. 2024-12-31. PMID:39738706. |
increased cardiovascular risk is much higher when acromegaly is complicated with diabetes, thus requiring a holistic management that addresses also these specific characteristics which differ from those of classical type 2 diabetes.the optimal management of diabetes in acromegaly requires not only an effective control of carbohydrate disturbances per se, but also the concurrent control of gh hypersecretion as it will directly impact on glucose control. |
2024-12-31 |
2025-01-03 |
Not clear |
| Betina Biagetti, Marta Araujo-Castro, Mónica Marazuela, Manel Puig-Doming. Treatment of acromegaly-induced diabetes: an updated proposal. Pituitary. vol 28. issue 1. 2024-12-31. PMID:39738706. |
if surgical treatment is not effective to normalize gh and igf-1 levels, pharmacologic therapy for acromegaly must consider the metabolic effects that the different drugs may induce, as some of them may worsen carbohydrate metabolism. |
2024-12-31 |
2025-01-03 |
Not clear |
| Yasuyuki Kinoshita, Akira Taguchi, Fumiyuki Yamasaki, Shumpei Onishi, Atsushi Tominaga, Nobutaka Hori. Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests. Pituitary. vol 28. issue 1. 2024-12-26. PMID:39724486. |
management policy for postoperative acromegaly patients with normal igf-1 and high gh levels on oral glucose tests. |
2024-12-26 |
2024-12-29 |
Not clear |
| Yasuyuki Kinoshita, Akira Taguchi, Fumiyuki Yamasaki, Shumpei Onishi, Atsushi Tominaga, Nobutaka Hori. Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests. Pituitary. vol 28. issue 1. 2024-12-26. PMID:39724486. |
acromegaly patients occasionally achieve either of the remission criterion of igf-1 or gh level postoperatively; however, treatment for patients with discordant igf-1 and gh levels remains unclear. |
2024-12-26 |
2024-12-29 |
Not clear |
| Haixiang Li, Ziqi Li, Tianshun Feng, Yuyang Chen, Jiansheng Zhong, Liangfeng Wei, Shousen Wan. Predictors of growth hormone level on postoperative day one in patients with acromegaly. Endocrine. 2024-12-20. PMID:39707075. |
the growth hormone (gh) level on postoperative day one (pod1), i.e., pod1gh, holds significant value in assessing surgical efficacy and predicting long-term remission in patients with acromegaly. |
2024-12-20 |
2024-12-24 |
Not clear |
| Haixiang Li, Ziqi Li, Tianshun Feng, Yuyang Chen, Jiansheng Zhong, Liangfeng Wei, Shousen Wan. Predictors of growth hormone level on postoperative day one in patients with acromegaly. Endocrine. 2024-12-20. PMID:39707075. |
this study aims to explore the factors that influence the gh level of pod1 after microscopic transsphenoidal surgery (mtss) in patients with acromegaly, providing insights for preoperative clinical decisions. |
2024-12-20 |
2024-12-24 |
Not clear |
| Kevin C J Yuen, Rikke Hjortebjerg, Ashok Ainkaran Ganeshalingam, David R Clemmons, Jan Frysty. Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin. Frontiers in endocrinology. vol 15. 2024-12-12. PMID:39665021. |
disease states of gh excess (e.g., acromegaly) and gh deficiency (e.g., congenital isolated gh deficiency) are characterized by increased and decreased gh, igf-i and insulin levels, respectively, where the gh/igf-i relationship is reflected by a "primary association". |
2024-12-12 |
2024-12-14 |
Not clear |
| Reetobrata Basu, Cesar L Boguszewski, John J Kopchic. Growth Hormone Action as a Target in Cancer: Significance, Mechanisms and Possible Therapies. Endocrine reviews. 2024-12-10. PMID:39657053. |
hypo or hypersecretion of endocrine gh results in two pathologic conditions, namely gh deficiency (ghd) and acromegaly. |
2024-12-10 |
2024-12-21 |
Not clear |
| Reetobrata Basu, Cesar L Boguszewski, John J Kopchic. Growth Hormone Action as a Target in Cancer: Significance, Mechanisms and Possible Therapies. Endocrine reviews. 2024-12-10. PMID:39657053. |
this pleiotropy of gh's effects is puzzling, but the association with cancer-risk automatically raises a concern for patients with acromegaly and for individuals treated with gh. |
2024-12-10 |
2024-12-21 |
Not clear |
| Pietro Maffei, Francesca Dassi. Medical Treatment of Acromegaly: What's New? Frontiers of hormone research. vol 55. 2024-11-25. PMID:39586262. |
acromegaly is a chronic and progressive disorder caused by growth hormone (gh) and insulin-like growth factor 1 (igf-1) excess, responsible for the onset of multiple systemic complications. |
2024-11-25 |
2024-11-28 |
Not clear |
| Federica Guaraldi, Luisa Di Sciascio, Tarik Ziyad Tarik Shwaish, Matteo Zoli, Diego Mazzatenta, Sofia Asiol. GH-Secreting Adenoma or Tumor? Issues in Pituitary Neoplasms Nomenclature, Classification, and Characterization. Frontiers of hormone research. vol 55. 2024-11-25. PMID:39586264. |
acromegaly is a rare disorder characterized by chronic hypersecretion of growth hormone (gh) and, consequently, of its mediator, insulin-like growth factor 1 (igf-1), due in >95% of the cases to a gh-secreting pituitary adenoma (pa)/pituitary neuroendocrine tumor (pitnet). |
2024-11-25 |
2024-11-28 |
Not clear |
| Agnieszka Włochacz, Paweł Krzesiński, Beata Uziębło-Życzkowska, Przemysław Witek, Grzegorz Zieliński, Grzegorz Gielera. Echocardiographic and Impedance Cardiography Analysis of Left Ventricular Diastolic Function in Acromegaly Patients. Medical science monitor : international medical journal of experimental and clinical research. vol 30. 2024-11-22. PMID:39573826. |
background due to the chronic effects of excess growth hormone (gh) and insulin-like growth factor-1 (igf-1), patients with acromegaly (ac) may develop acromegalic cardiomyopathy with biventricular hypertrophy, systolic and diastolic dysfunction, resulting in congestive heart failure. |
2024-11-22 |
2024-11-24 |
Not clear |